ReviewCardiology and therapy2020
Dual Antiplatelet Therapy in Coronary Artery Disease.
Review in Cardiology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- The impact of anti-thrombotic therapy on bleeding outcomes and thrombosis following laparoscopic cholecystectomy: a meta-analysis.Updates in surgery · 2024Pooled it
- Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials.BMC cardiovascular disorders · 2024Pooled it
- Pooled it
- Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)-a randomized trial.Scientific reports · 2023Trial
- Cardiovascular Diseases: Exploring Epidemiology, Pathophysiology, Risk Factors, and Medicinal Plant-Based Therapies: A Narrative Review.Health science reports · 2026Article
- Lifestyle Behaviours and Antiplatelet Medication Adherence Among Post-Percutaneous Coronary Intervention Patients in Saudi Arabia: Implications for Holistic Cardiovascular Nursing Care.Healthcare (Basel, Switzerland) · 2026Article
- Patient Education Deficits and Medication Knowledge Gaps Among Post-Percutaneous Coronary Intervention Patients: A Cross-Sectional Study of Communication Quality and Adherence in Saudi Cardiac Care.Healthcare (Basel, Switzerland) · 2026Article
- Theory of Planned Behaviour Constructs as Predictors of Antiplatelet Medication Adherence Following Percutaneous Coronary Intervention: A Cross-Sectional Study in Saudi Arabia.Healthcare (Basel, Switzerland) · 2026Article
- Antithrombotic Polymers: A Narrative Review on Current and Future Strategies for Their Design, Synthesis, and Application.International journal of molecular sciences · 2026Review
- Percutaneous coronary intervention followed by intravascular brachytherapy for management of drug-eluting stents in-stent restenosis in patients with complex coronary artery lesions.Journal of contemporary brachytherapy · 2025Article
- Pharmacotherapy, Lifestyle Modification, and Cardiac Rehabilitation after Myocardial Infarction or Percutaneous Intervention.US cardiology · 2025Review
- Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Therapeutic Antithrombotic Agent Use and Bleeding Risk in Retrobulbar Anesthesia for Outpatient Ophthalmic Surgery.Cureus · 2024Article
- Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention.Journal of endocrinological investigation · 2024Article
- The Efficacy and Safety of Antiplatelet Therapy in Patients With Acute Coronary Syndrome: A Scoping Review.Cureus · 2023Article
- Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review article.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Review
- Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis.Frontiers in cardiovascular medicine · 2023Review
- Prolonged dual antiplatelet therapy after drug-eluting stent implantation improves long-term prognosis for acute coronary syndrome: five-year results from a large cohort study.World journal of emergency medicine · 2023Article
- Development of a carotid artery thrombolysis stroke model in mice.Blood advances · 2022Article
- Prognostic Modelling Studies of Coronary Heart Disease-A Systematic Review of Conventional and Genetic Risk Factor Studies.Journal of cardiovascular development and disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute coronary syndrome (ACS) is principally driven by platelet aggregation. Dual antiplatelet therapy (DAPT) has demonstrated a reduction in recurrent ischemic events. The newer antiplatelets ticagrelor and prasugrel have demonstrated superiority over clopidogrel. While prasugrel demonstrated benefit in patients scheduled for percutaneous intervention (PCI), benefits of ticagrelor were seen irrespective of the treatment strategy. Current guidelines recommend the use of DAPT for 1 year in all patients with ACS. Ticagrelor 60 mg is recommended for up to 3 years in high-risk patients. DAPT and Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE DAPT) scores are tools to support decision-making in deciding duration of dual antiplatelet therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.